Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series
Brain and Behavior · 2026
DOI: 10.1002/brb3.71157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Jing Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission of Hubei Province scientific research project, Natural Science Foundation of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Refractory ocular myasthenia gravis (MG) represents a significant therapeutic challenge, as conventional immunotherapies often prove ineffective. Telitacicept, a recombinant B‐lymphocyte stimulator receptor‐antibody fusion protein, offers a novel immunomodulatory approach. This retrospective study evaluates its efficacy and safety in patients with MG‐associated refractory ocular symptoms.
Methods
This is a single‐center retrospective cohort study. evaluated patients with refractory ocular symptoms who received telitacicept weekly between August 2024 and January 2025. We evaluated treatment efficacy using Myasthenia Gravis Foundation of America post‐intervention status (MGFA‐PIS), Myasthenia Gravis Impairment Index‐patient‐reported outcome (MGII‐PRO), quantitative MG (QMG), and MG activity of daily living (ADL) scores, as well as the reduction in daily prednisone dosage at baseline and each month following treatment. The safety assessment was also evaluated.
Results
Seven MGFA class 1 patients (5 females, 2 males) were enrolled, with a median onset age of 6 years (interquartile range [IQR] 2–21) and a median disease duration of 98 months (IQR 46–121). MG‐ADL scores showed significant reduction with prolonged follow‐up. 6/7 patients achieved ≥2‐point MG‐ADL improvement by the third follow‐up. 4/6 patients reached minimal symptom expression at the fifth follow‐up. The average ocular MG‐ADL, MGII‐PRO, and QMG scores revealed statistically significant improvements at the third month of follow‐up, sustained through the sixth month. The regimen exhibited excellent tolerability, with no severe adverse events (e.g., hypersensitivity reactions, infections) reported.
Conclusion
Our preliminary findings indicate that telitacicept represents a promising and well‐tolerated adjunct therapy for refractory ocular symptoms in MG, providing significant clinical evidence to support this novel therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Förderung
- Health Commission of Hubei Province scientific research project
- Natural Science Foundation of Hubei Province
- National Natural Science Foundation of China
Zitieren
APA
Lin, J., Li, Y., Gui, M., Bu, B., & Li, Z. (2026). Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series. Brain and Behavior. https://doi.org/10.1002/brb3.71157
Vancouver
Lin J, Li Y, Gui M, Bu B, Li Z. Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series. Brain and Behavior. 2026. doi:10.1002/brb3.71157
BibTeX
@article{Lin2026,
author = {Lin, Jing and Li, Yue and Gui, Mengcui and Bu, Bitao and Li, Zhijun},
title = {Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series},
journal = {Brain and Behavior},
year = {2026},
doi = {10.1002/brb3.71157}
}
EUVIMED